BGB-102

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

BGB-102 是多重激酶抑制剂，能够抑制 EGFR，HER2 和 HER4，IC50 值分别为 9.6 nM，18 nM 和 40.3 nM。

BGB-102 is a potent multi-kinase inhibitor against EGFR, HER2, and HER4 with IC50s of 9.6 nM, 18 nM and 40.3 nM, respectively.

JNJ-26483327 (5 μM or 10 μM) with Herceptin treatment decreases HER2 phosphorylation in SKBR3 cells. JNJ-26483327 exerts greater inhibition of cell viability after 3, 6, or 8 d of treatment compared to Herceptin or JNJ-26483327 alone. JNJ-26483327 with TAPI-1 exerts less cell viability inhibition than Herceptin alone in both SKBR3 and BT474 cells.

JNJ-26483327 (75 mg/kg, p.o.) delays xenograft tumour growth compared to vehicle treatment, but when combines with Herceptin, they can abrogate the PKB feedback loop and is synergistic in inhibition of xenograft tumour growth.

——

Angiogenesis

FLT

FLT | VEGFR | EGFR | Src

——

——

807640-87-5

457.36

C22H25BrN4O2

>98% (HPLC)

——

BrC1=CC=C2C(=C1)NC=3N=CN=C4C=C(OC)C(OCCCCCN(C)C2)=CC43

——

(-20℃)

With Ice Pack

≥ 2 years